New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
04:55 EDTACHC, ACHC, ACHC, BABY, BABY, BABY, CNC, CNC, CNC, INCY, INCY, INCY, AUXL, AUXL, AUXL, HGR, HGR, HGR, ALKS, ALKS, ALKS, ACHN, ACHN, ACHN, MZOR, MZOR, MZOR, LMNX, LMNX, LMNX, IDIX, IDIX, IDIXUBS to hold a conference
Global Healthcare Conference to be held in New York on May 19-21.
News For IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
December 16, 2014
07:57 EDTCNCCentene price target raised to $118 from $102 at Credit Suisse
Subscribe for More Information
December 15, 2014
13:06 EDTACHNAchillion December volatility elevated at 285
Achillion December call option implied volatility is at 285, January is at 231; compared to its 26-week average of 153 according to Track Data, suggesting large price movement.
08:41 EDTCNCCentene price target raised to $120 from $100 at Leerink
Subscribe for More Information
07:02 EDTALKSAlkermes announces initiation of Phase 1 aripiprazole lauroxil study
Subscribe for More Information
05:58 EDTACHNStocks with implied volatility above IV index mean; ACHN DG
Subscribe for More Information
December 12, 2014
08:01 EDTINCYPiper predicts two large-cap biotechs could be acquired in 2015
Subscribe for More Information
06:06 EDTCNCCentene sees FY15 EPS $5.05-$5.35, consensus $4.92
Sees FY15 premium and service revenues $20.3B-$20.8B.
06:05 EDTCNCCentene backs FY14 EPS view of $4.35-$4.50, consensus $4.28
Subscribe for More Information
December 11, 2014
17:04 EDTAUXLEndo registration statement relating to Auxilium declared effective by SEC
Subscribe for More Information
06:44 EDTHGRHanger management to meet with SunTrust
Meeting to be held in Texas on December 16 hosted by SunTrust.
December 10, 2014
14:45 EDTCNCDeal would block payments to health insurance companies, The Hill says
Subscribe for More Information
12:21 EDTHGRInvesco Ltd. reports 10.4% passive stake in Hanger
Subscribe for More Information
December 9, 2014
10:31 EDTCNCCentene to host investor meeting
Subscribe for More Information
07:11 EDTINCYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
06:07 EDTMZORMazor Robotics receives purchase orders for three Renaissance systems in Asia
Subscribe for More Information
December 8, 2014
13:07 EDTINCYNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
11:49 EDTACHNAchillion December volatility elevated
Subscribe for More Information
08:50 EDTALKSAlkermes price target raised to $63 on pipeline catalysts at Credit Suisse
Subscribe for More Information
08:32 EDTACHNTrout Group to hold events at ASH 2014
Subscribe for More Information
06:12 EDTACHNStocks with implied volatility above IV index mean; LULU ACHN
Stocks with implied volatility above IV index mean; lululemon (LULU) 53, Achillion (ACHN) 216 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use